Orchestra BioMed Holdings, Inc. (OBIO)

Over the past six months, OBIO's stock price has been impacted by several events. As of May 8, 2026, OBIO's stock was trading around $4.04, reflecting a 2.7% decrease since January 1, 2026. In May 2026, Orchestra BioMed received a $15 million investment from Ligand and a $20 million payment from Medtronic. In April 2026, the FDA granted Orchestra BioMed an additional Breakthrough Device Designation for its AVIM Therapy, and the company announced presentations of AVIM Therapy clinical and mechanistic data at the Heart Rhythm Society (HRS) 2026 Annual Meeting. In March 2026, Orchestra BioMed reported its full-year 2025 financial results and provided a fourth-quarter business update, reporting $0.26 earnings per share for the quarter, beating estimates of -$0.38. In February 2026, insider buying activity was noted, and Medtronic plc filed a Form 13G indicating ownership of 10,078,625 shares. News updates from Fintel were reported in December 2025. In November 2025, Fintel and Zacks reported news, and the company held a 3Q25 Corporate Update Call, with Perceptive Advisors LLC, Perceptive Life Sciences Master Fund Ltd, and Joseph Edelman filing a Form 13G indicating ownership of 5,679,480 shares.

Information regarding demand seasonality for Orchestra BioMed Holdings, Inc.'s products and services is not explicitly available in the provided search results. As a biomedical company focused on therapeutic devices for conditions like hypertension and atherosclerotic artery disease, demand for its products is typically driven by medical need, disease prevalence, and regulatory approvals rather than seasonal consumer patterns.

Orchestra BioMed Holdings, Inc. (OBIO) is a biomedical company based in the United States, operating within the Healthcare sector and the Biotechnology industry. The company focuses on accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. Its major product candidates include Atrioventricular Interval Modulation (AVIM) Therapy / BackBeat Cardiac Neuromodulation Therapy (CNT) for hypertension, Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for atherosclerotic artery disease, Cardiac Neuromodulation Therapy for heart failure (CNT-HF), FreeHold devices for minimally invasive surgery, and the Pure-Vu system for gastrointestinal tract cleansing. The company collaborates with major players like Medtronic, Inc. for AVIM therapy and Terumo Corporation for Virtue SAB.

Orchestra BioMed Holdings, Inc. is headquartered in New Hope, Pennsylvania, United States. While its primary operations are in the U.S., its business model emphasizes strategic collaborations with leading medical device companies to drive successful global commercialization of its products.

Orchestra BioMed Holdings, Inc. has maintained a generally positive brand reputation over the past year, primarily driven by positive analyst sentiment and significant regulatory and financial milestones. The company has received a consensus rating of "Moderate Buy" from analysts, with an average 1-year price target of $14.25. Receiving an additional FDA Breakthrough Device Designation for AVIM Therapy, presentations of positive clinical and mechanistic data for AVIM Therapy at major medical conferences, securing substantial investments from Ligand and Medtronic, beating earnings per share estimates in Q4 2025, and insider buying activity have all contributed positively to the company's reputation. No explicitly negative events significantly impacting Orchestra BioMed's reputation in the past year were found in the search results.

Orchestra BioMed Holdings, Inc. has significant institutional ownership, with 70 institutional owners and shareholders holding a total of 22,009,937 shares, representing approximately 53.20% of the stock, while insiders hold 8.10%. Major institutional and individual owners include RTW Investments, LP, Perceptive Advisors LLC / Perceptive Life Sciences Master Fund, Ltd., The Vanguard Group Inc., Alyeska Investment Group, L.P., BlackRock, Inc., Affinity Asset Advisors, LLC, Geode Capital Management, LLC, Price T Rowe Associates Inc /md/, Charles Schwab Investment Management Inc, Knott David M Jr, Medtronic plc (a 10% owner), Joseph Edelman (10% owner), and David P. Hochman (CEO and insider).